Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab.
Takayuki NakayamaHideki TakeshitaMakoto KagawaSatoshi WashinoSuguru ShirotakeYuji MiuraYoji HyodoKeita IzumiMasaharu InoueYoh MatsuokaTomoaki MiyagawaMasafumi OyamaKazutaka SaitoSatoru KawakamiPublished in: International journal of clinical oncology (2024)
Both NLR and CRP were considered useful biomarkers for understanding the prognosis during nivolumab plus ipilimumab therapy. Furthermore, an NLR of ≥ 4.8 and CRP of ≥ 1.0 mg/dL at week 9 are helpful in reconsidering treatment continuation.